Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

[1]  P. Trouillas,et al.  Intracerebral haematoma after application of nicotine patch , 1995, The Lancet.

[2]  P. Hjemdahl,et al.  Acute effects of low dose nicotine gum on platelet function in non-smoking hypertensive and normotensive men , 2004, European Journal of Clinical Pharmacology.

[3]  N. Benowitz,et al.  Dose‐related cardiovascular and endocrine effects of transdermal nicotine , 1998, Clinical pharmacology and therapeutics.

[4]  Office on Smoking How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General , 2010 .

[5]  W. Little,et al.  Myocardial infarction in a patient who smoked while wearing a nicotine patch. , 1994, Annals of internal medicine.

[6]  M. Verani,et al.  Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. , 1997, Journal of the American College of Cardiology.

[7]  K. Wilson,et al.  Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals , 2010, Tobacco induced diseases.

[8]  Jacob Abelson,et al.  Reviews , 1974 .

[9]  Dan Tzivoni,et al.  Cardiovascular Safety of Transdermal Nicotine Patches in Patients with Coronary Artery Disease who Try to Quit Smoking , 1998, Cardiovascular Drugs and Therapy.

[10]  D. Faulds,et al.  Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. , 1992, Drugs.

[11]  J. Ottervanger,et al.  Acute myocardial infarction while using the nicotine patch. , 1995, Chest.

[12]  S. Glantz,et al.  Effective tobacco control is key to rapid progress in reduction of non-communicable diseases , 2012, The Lancet.

[13]  H. McRobbie,et al.  Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis , 2013, Thorax.

[14]  K. Perkins Smoking Cessation in Women , 2001, CNS drugs.

[15]  D. Singer,et al.  Bupropion for smokers hospitalized with acute cardiovascular disease. , 2006, The American journal of medicine.

[16]  M. Fiore,et al.  The Effectiveness of the Nicotine Patch for Smoking Cessation , 1994 .

[17]  J. Issa,et al.  Effectiveness of sustained-release bupropion in the treatment of smoker patients with cardiovascular disease. , 2007, Arquivos brasileiros de cardiologia.

[18]  Qi Zhang,et al.  Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. , 1993, Journal of the American College of Cardiology.

[19]  N. Rigotti,et al.  Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial , 2010, Circulation.

[20]  S. Roose Considerations for the use of antidepressants in patients with cardiovascular disease. , 2000, American heart journal.

[21]  J. McNeil,et al.  Predictors and Timing of Adverse Experiences During Transdermal Nicotine Therapy , 1999, Drug safety.

[22]  Jonathan A. Zlabek,et al.  Nicotine replacement therapy and cardiovascular disease. , 2005, Mayo Clinic proceedings.

[23]  J. Issa,et al.  Efetividade da Bupropiona no Tratamento de Pacientes Tabagistas com Doença Cardiovascular Effectiveness of Sustained-Release Bupropion in the Treatment of Smoker Patients with Cardiovascular Disease , 2007 .

[24]  J. Prochaska,et al.  Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[25]  Richard Platt,et al.  Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. , 2013, JAMA internal medicine.

[26]  B. Stricker,et al.  Vasculitis attributed to the nicotine patch (Nicotinell) , 1996, The British journal of dermatology.

[27]  R. J. Mather,et al.  Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid , 2007, Neuropharmacology.

[28]  Selma Ari,et al.  The effect of varenicline on heart rate variability in healthy smokers and nonsmokers , 2011, Autonomic Neuroscience.

[29]  A. Blann,et al.  The Influence of Smoking and of Oral and Transdermal Nicotine on Blood Pressure, and Haematology and Coagulation Indices , 1997, Thrombosis and Haemostasis.

[30]  N. Herity,et al.  Acute myocardial infarction soon after nicotine replacement therapy. , 2001, QJM : monthly journal of the Association of Physicians.

[31]  L. Hillis,et al.  Intranasal nicotine spray does not augment the adverse effects of cigarette smoking on myocardial oxygen demand or coronary arterial dimensions. , 1996, The American journal of medicine.

[32]  H. Svanström,et al.  Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study , 2012, BMJ : British Medical Journal.

[33]  J. Pierce Stroke following Application of a Nicotine Patch , 1994, The Annals of pharmacotherapy.

[34]  K. Haustein,et al.  Comparison of the effects of combined nicotine replacement therapy vs. cigarette smoking in males. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[35]  S. Kimmel,et al.  Risk of acute first myocardial infarction and use of nicotine patches in a general population. , 2001, Journal of the American College of Cardiology.

[36]  Xin Wang,et al.  Endogenous acetylcholine and nicotine activation enhances GABAergic and glycinergic inputs to cardiac vagal neurons. , 2003, Journal of neurophysiology.

[37]  B. Steele,et al.  The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. , 1996, The New England journal of medicine.

[38]  Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. , 1994, Archives of internal medicine.

[39]  R. Ritz,et al.  Influence of moderately elevated levels of carboxyhemoglobin on the course of acute ischemic heart disease. , 1985, Respiration; international review of thoracic diseases.

[40]  S. Greenland,et al.  A Meta-Analysis to Assess the Incidence of Adverse Effects Associated with the Transdermal Nicotine Patch , 1998, Drug safety.

[41]  N. Benowitz Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. , 2003, Progress in cardiovascular diseases.

[42]  R. Hurst,et al.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. , 2007, Neuropharmacology.

[43]  A. Sanfilippo,et al.  Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. , 1997, The Canadian journal of cardiology.

[44]  R. Gonthier,et al.  Myocardial infarction and nicotine patch: a contributing or causative factor? , 1993, European heart journal.

[45]  L. Stead,et al.  Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. , 2014, Addiction.

[46]  D. Cook,et al.  Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. , 2000, Archives of internal medicine.

[47]  R. Perera,et al.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.

[48]  Dependence Update Panel,et al.  A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. , 2008, American journal of preventive medicine.

[49]  A. Nitenberg,et al.  Effects of nicotine gum on coronary vasomotor responses during sympathetic stimulation in patients with coronary artery stenosis. , 1999, Journal of cardiovascular pharmacology.

[50]  M. Beyens,et al.  Serious Adverse Reactions of Bupropion for Smoking Cessation , 2008, Drug safety.

[51]  A. Malliani,et al.  Autonomic effects of nicotine patch administration in habitual cigarette smokers: a double-blind, placebo-controlled study using spectral analysis of RR interval and systolic arterial pressure variabilities. , 1998, Journal of cardiovascular pharmacology.

[52]  B. Walsh,et al.  Cardiovascular effects of bupropion in depressed patients with heart disease. , 1991, The American journal of psychiatry.

[53]  C. Furberg,et al.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.

[54]  Timothy B. Baker,et al.  The Effectiveness of the Nicotine Patch for Smoking Cessation. A Meta-analysis , 1995 .

[55]  Patricia Dolan Mullen,et al.  Treating tobacco use and dependence: clinical practice guideline , 2000 .

[56]  Kristian Thorlund,et al.  Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis , 2014, Circulation.

[57]  T. Payne,et al.  Treating nicotine dependence. , 2003, The American journal of the medical sciences.

[58]  S. Tonstad,et al.  Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. , 2003, European heart journal.

[59]  M. Harrison‐Woolrych,et al.  Cardiovascular Events in Patients taking Varenicline , 2012, Drug Safety.

[60]  Tim Lancaster,et al.  Nicotine receptor partial agonists for smoking cessation. , 2010, The Cochrane database of systematic reviews.